News und Analysen
![Pfizer Outlines Five-Point Plan to Battle COVID-19](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Pfizer Outlines Five-Point Plan to Battle COVID-19
Pfizer today issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.
Dr. Albert Bourla, Chairman
![Chemed Corporation’s Board of Directors Authorizes an Additional $250 Million for Stock Repurchase](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Chemed Corporation’s Board of Directors Authorizes an Additional $250 Million for Stock Repurchase
Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has formally authorized an additional $250 million for stock repurchase under Chemed’s existing share repurchase program
![QIAGEN Gains BARDA Funding for Approval Process of QIAstat-Dx Test Kit for SARS-CoV-2 Coronavirus](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
QIAGEN Gains BARDA Funding for Approval Process of QIAstat-Dx Test Kit for SARS-CoV-2 Coronavirus
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will develop a new QIAstat-Dx test kit to differentiate the novel SARS-CoV-2 coronavirus from 21 other serious respiratory
![Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the
![Savara Reports Fourth Quarter / Year-End 2019 Financial Results and Provides Business Update](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Savara Reports Fourth Quarter / Year-End 2019 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the fourth quarter and full year ending December 31, 2019 and provided a business update.
This
![Agilent Receives Two Scientists’ Choice Awards](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Agilent Receives Two Scientists’ Choice Awards
Agilent Technologies Inc. (NYSE: A) today announced that two of the company’s instruments have received Scientists’ Choice awards. The Agilent 8890 GC system won for Best New Separations Product
![Preclinical Data Show Tumor Treating Fields Induces Immunogenic Cell Death Resulting in Enhanced Antitumor Efficacy When Combined with Anti-PD-1 Therapy](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Preclinical Data Show Tumor Treating Fields Induces Immunogenic Cell Death Resulting in Enhanced Antitumor Efficacy When Combined with Anti-PD-1 Therapy
Novocure (NASDAQ: NVCR) announced today that preclinical data on Tumor Treating Fields in combination with anti-PD-1 therapy were published in the peer-reviewed journal, Cancer Immunology,
![Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) , a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and
![Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance
Regulatory News:
Vifor Pharma Group recorded strong financial and operational performance in 2019 by focusing on its three strategic growth drivers while continuing to invest in its pipeline. The
![Vifor Pharma Gruppe erzielt 2019 starkes Wachstum und übertrifft die angehobene Prognose](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Vifor Pharma Gruppe erzielt 2019 starkes Wachstum und übertrifft die angehobene Prognose
Regulatory News:
Die Vifor Pharma Gruppe erzielte 2019 ein starkes finanzielles und operatives Ergebnis dank Fokus auf die drei strategischen Wachstumstreiber und gezielten Investitionen in die
![Hanger Reports Fourth Quarter 2019 Results and Provides 2020 Outlook](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Hanger Reports Fourth Quarter 2019 Results and Provides 2020 Outlook
Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced its financial results for the fourth quarter and year ended
![Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
![Transgene: Major R&D Milestones Achieved in 2019 and Strong Clinical Activity In 2020](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Transgene: Major R&D Milestones Achieved in 2019 and Strong Clinical Activity In 2020
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, publishes its financial results
![Inovio Pharmaceuticals: Berühmt-berüchtigter Shortseller attackiert!](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Inovio Pharmaceuticals: Berühmt-berüchtigter Shortseller attackiert!
Die Aktie des vergleichsweise kleinen Biotechunternehmens Inovio Pharmaceuticals (WKN: A115GK) sprang zuletzt wild hin und her. Dafür gibt es natürlich auch gute Gründe.
Zunächst schoss die Aktie
![Newron Updates On STARS Study FDA Interaction](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Newron Updates On STARS Study FDA Interaction
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
![US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on
![Charles River Laboratories To Participate In Barclays Global Healthcare Conference](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Charles River Laboratories To Participate In Barclays Global Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will participate in the Barclays Global Healthcare Conference. The Company will present on Wednesday, March 11th
![Symmetry, das LivaNova VNS Therapy-System für schwer zu behandelnde Depressionen, erhält CE-Prüfzeichen](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Symmetry, das LivaNova VNS Therapy-System für schwer zu behandelnde Depressionen, erhält CE-Prüfzeichen
LivaNova PLC (NASDAQ:LIVN), ein marktführendes medizintechnisches Innovationsunternehmen, gab heute bekannt, dass sein System Vagus Nerve Stimulation Therapy® (VNS Therapy) Symmetry™ die
![Humana Takes Steps to Care for Members in Response to Coronavirus](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Humana Takes Steps to Care for Members in Response to Coronavirus
Humana Inc. (NYSE: HUM) announced today several actions in response to the increased spread of the coronavirus (COVID-19).
“As we navigate the spread of the coronavirus, our top priority is the
![American Renal Associates Holdings, Inc. Announces Fourth Quarter 2019 Earnings Release Date and Conference Call](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
American Renal Associates Holdings, Inc. Announces Fourth Quarter 2019 Earnings Release Date and Conference Call
American Renal Associates Holdings, Inc. (NYSE: ARA), a leading kidney care and dialysis provider focused on partnering with local nephrologists, announced today that it will hold its fourth
![Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization & development collaboration](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization & development collaboration
Regulatory News:
Curadigm, an early-stage nanotechnology company committed to improving treatment outcomes by redefining the therapeutic balance between bioavailability, toxicity, and efficacy
![LivaNova VNS Therapy System, Symmetry, Granted CE Mark for Difficult-to-Treat Depression](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
LivaNova VNS Therapy System, Symmetry, Granted CE Mark for Difficult-to-Treat Depression
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Vagus Nerve Stimulation Therapy® (VNS Therapy) System, Symmetry™, earned CE Mark approval
![Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
![Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the fourth quarter and year ended December 31, 2019. Amounts, unless
![Savara to Report Fourth Quarter/Year-End 2019 Financial Results and Provide Business Update](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Savara to Report Fourth Quarter/Year-End 2019 Financial Results and Provide Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report fourth quarter/year-end 2019 financial results and provide a business update on Thursday